<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2024-2S-38-43</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-2314</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ</subject></subj-group></article-categories><title-group><article-title>Pain in patients with neuromyelitis optica spectrum disorders</article-title><trans-title-group xml:lang="ru"><trans-title>Болевой синдром у пациентов с заболеваниями спектра оптиконевромиелита</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6004-9111</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новикова</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikova</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>129110, Москва, ул. Щепкина, 61/2</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2988-5706</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Котов</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kotov</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>129110, Москва, ул. Щепкина, 61/2</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8706-7317</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Котов</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kotov</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергей Викторович Котов</p><p>129110, Москва, ул. Щепкина, 61/2</p></bio><bio xml:lang="en"><p>Sergey Viktorovich Kotov</p><p>61/2, Shchepkina St., Moscow 129110</p></bio><email xlink:type="simple">kotovsv@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>M.F. Vladimirsky Moscow Regional Research Clinical Institute</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>07</day><month>08</month><year>2024</year></pub-date><volume>16</volume><issue>0</issue><issue-title>(Suppl. 2)</issue-title><fpage>38</fpage><lpage>43</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Novikova E.S., Kotov A.S., Kotov S.V., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Новикова Е.С., Котов А.С., Котов С.В.</copyright-holder><copyright-holder xml:lang="en">Novikova E.S., Kotov A.S., Kotov S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/2314">https://nnp.ima-press.net/nnp/article/view/2314</self-uri><abstract><p>Neuromyelitis optica spectrum disorders (NMOSD) are a group of chronic autoimmune diseases of the central nervous system with a relapsing course. Unfortunately, the symptoms of exacerbation cannot always be completely stopped, and in addition to motor disorders, chronic pain and depression can worsen the patient's condition. Currently, one of the factors that significantly affects the quality of life of patients in this group is chronic, debilitating pain.</p><sec><title>Objective</title><p>Objective: to determine the prevalence of the pain syndrome in the population of NMOSD patients in Moscow region, to investigate its clinical characteristics and its impact on quality of life.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 33 patients with NMOSD (6 men and 27 women) aged 22 to 64 years. The following criteria were used to assess the neurological condition, presence and severity of the pain syndrome: Expanded Disability Status Scale (EDSS), Diagnostic Neuropathic Pain Questionnaire (DN4), Pain Detect Questionnaire (PDQ), McGill Pain Questionnaire (MPQ), SF-36 Quality of Life Questionnaire, Beck Depression Inventory and MRI data.</p></sec><sec><title>Results</title><p>Results. Among the patients analysed, the pain syndrome occurred in 19 patients (57.6%): 4 patients with NMOSD without antibodies against aquaporin-4 (AQP4-) and 15 with antibodies against AQP4 (AQP4+). In this group, neuropathic pain was observed in 14 patients (11 – AQP4+ and three – AQP4-), pain due to spasticity in 6 patients (5 – AQP4+ and 1 – AQP4-), painful tonic spasms in 2 patients with AQP4+ and neuropathic itching – in 1 patient with AQP4-. According to the questionnaires of the seropositive patients, the median DN4 was 3 [2; 3] (here and below the data are given in Me format [25th; 75th percentile]), PDQ – 6 [5; 12], on the MPQ scale: pain rank index – 11 [9; 15], index of the number of selected symptoms – 3 [3; 4], pain intensity – 2 [1; 3]. The results for the physical and psychological health domains of the SF36 questionnaire were 35.9 [6.5; 36] and 50.5 [5; 51.5] respectively. Among AQP4+ patients, 7 out of 15 patients were diagnosed with depression; in the AQPpatients, only one man was diagnosed with depression. There was a statistically significant correlation between the age of the patients and pain level: neuropathic pain according to DN4 was more pronounced in younger patients (p=0.009), and neuropathic pain was significantly more severe in patients with an early onset of the disease (p=0.04).</p></sec><sec><title>Conclusion</title><p>Conclusion. There is currently no clear approach for the treatment of pain in NMOSD. In the present small study, different causes of pain were identified, depending on the location and severity of the lesion, the age of the patient and the duration of the disease. The most important factor in the prevention and treatment of pain syndrome in NMOSD is probably adequate immunotherapy of the disease.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Заболевания спектра оптиконевромиелита (ЗСОНМ) – группа хронических аутоиммунных заболеваний центральной нервной системы с рецидивирующим течением. К сожалению, симптоматику обострения не всегда удается полностью купировать и помимо двигательных нарушений состояние пациента может отягощаться хроническим болевым синдромом и депрессией. На данный момент одним из факторов, значимо влияющих на качество жизни пациентов из этой группы, является именно хроническая, изнуряющая боль.</p><p>Целью нашего исследования было оценить распространенность болевого синдрома внутри популяции пациентов с ЗСОНМ в Московской области, изучить ее клинические характеристики и влияние на качество жизни.</p><sec><title>Материал и методы</title><p>Материал и методы. В исследование вошли 33 пациента с ЗСОНМ (из них 6 мужчин и 27 женщин) в возрасте от 22 до 64 лет. Для оценки неврологического статуса, наличия и степени выраженности болевого синдрома использовались: индекс Расширенной шкалы оценки степени инвалидизации (Expanded Disability Status Scale, EDSS), Диагностический опросник невропатической боли (Diagnostic Neuropathic Pain Questionnaire, DN4), опросник Pain Detect (Pain Detect Questionnaire, PDQ), Опросник боли МакГилла (McGill Pain Questionare, MPQ), опросник оценки качества жизни SF-36, шкала Бека для оценки депрессии, а также данные МРТ.</p></sec><sec><title>Результаты</title><p>Результаты. Среди обследованных пациентов болевой синдром встречается у 19 (57,6%) больных: четырех пациентов с ЗСОНМ без антител к аквапорину-4 (AQP4-) и 15 человек с антителами к AQP4 (AQP4+). В этой группе невропатическая боль выявлена у 14 пациентов (11 – AQP4+ и три –AQP4-), боль, обусловленная спастичностью, – у шести пациентов (пять – AQP4+ и один – AQP4-), болевые тонические спазмы – у двух пациентов с AQP4+ и невропатический зуд – у одного пациента с AQP4-. Согласно данным опросников серопозитивных пациентов, медиана DN4 составила 3 [2; 3] (здесь и далее данные приведены в формате Me [25-й; 75-й перцентили]), PDQ – 6 [5; 12], по шкале MPQ: ранговый индекс боли – 11 [9; 15], индекс числа выбранных дескриптов – 3 [3; 4], интенсивность боли – 2 [1; 3]. Результаты по физическому и психологическому компонентам здоровья опросника SF36 составили 35,9 [6,5; 36] и 50,5 [5; 51,5] соответственно. Среди AQP4+ пациентов депрессия отмечена у 7 из 15 больных, у АQP-пациентов депрессия была выявлена только у одного мужчины. Выявлена статистически значимая связь между возрастом пациентов и степенью болевого синдрома: у более молодых больных невропатическая боль была более выраженной по данным DN4 (р=0,009), также невропатическая боль была значимо сильнее у пациентов с ранним дебютом заболевания (р=0,04).</p></sec><sec><title>Заключение</title><p>Заключение. В настоящее время не сформирован однозначный подход к терапии боли при ЗСОНМ. В представленном небольшом исследовании были отмечены различные причины возникновения болевого синдрома, обусловленные локализацией и тяжестью поражения, возрастом больных и длительностью течения болезни. Вероятно, основным фактором предупреждения и терапии болевого синдрома при ЗСОНМ является адекватная иммунотерапия заболевания.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>заболевания спектра оптиконевромиелита</kwd><kwd>аквапорин-4</kwd><kwd>боль</kwd><kwd>невропатическая боль</kwd></kwd-group><kwd-group xml:lang="en"><kwd>neuromyelitis optica spectrum disorders</kwd><kwd>aquaporin-4</kwd><kwd>pain</kwd><kwd>neuropathic pain</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование не имело спонсорской поддержки</funding-statement><funding-statement xml:lang="en">The investigation has not been sponsored</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012 Jan 19;9:14. doi: 10.1186/1742-2094-9-14</mixed-citation><mixed-citation xml:lang="en">Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012 Jan 19;9:14. doi: 10.1186/1742-2094-9-14</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ayzenberg I, Richter D, Henke E, et al; NEMOS (Neuromyelitis Optica Study Group). Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients. Neurol Neuroimmunol Neuroinflamm. 2021 Apr 20;8(3):e985. doi: 10.1212/NXI.0000000000000985</mixed-citation><mixed-citation xml:lang="en">Ayzenberg I, Richter D, Henke E, et al; NEMOS (Neuromyelitis Optica Study Group). Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients. Neurol Neuroimmunol Neuroinflamm. 2021 Apr 20;8(3):e985. doi: 10.1212/NXI.0000000000000985</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kanamori Y, Nakashima I, Takai Y, et al. Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology. 2011 Aug 16;77(7):652-8. doi: 10.1212/WNL.0b013e318229e694. Epub 2011 Aug 3.</mixed-citation><mixed-citation xml:lang="en">Kanamori Y, Nakashima I, Takai Y, et al. Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology. 2011 Aug 16;77(7):652-8. doi: 10.1212/WNL.0b013e318229e694. Epub 2011 Aug 3.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Qian P, Lancia S, Alvarez E, et al. Association of neuromyelitis optica with severe and intractable pain. Arch Neurol. 2012 Nov;69(11):1482-7. doi: 10.1001/archneurol.2012.768</mixed-citation><mixed-citation xml:lang="en">Qian P, Lancia S, Alvarez E, et al. Association of neuromyelitis optica with severe and intractable pain. Arch Neurol. 2012 Nov;69(11):1482-7. doi: 10.1001/archneurol.2012.768</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Pellkofer HL, Havla J, Hauer D, et al. The major brain endocannabinoid 2-AG controls neuropathic pain and mechanical hyperalgesia in patients with neuromyelitis optica. PLoS One. 2013 Aug 9;8(8):e71500. doi: 10.1371/journal.pone.0071500</mixed-citation><mixed-citation xml:lang="en">Pellkofer HL, Havla J, Hauer D, et al. The major brain endocannabinoid 2-AG controls neuropathic pain and mechanical hyperalgesia in patients with neuromyelitis optica. PLoS One. 2013 Aug 9;8(8):e71500. doi: 10.1371/journal.pone.0071500</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao S, Mutch K, Elsone L, et al. Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life. Mult Scler. 2014 Oct;20(12):1658-61. doi: 10.1177/1352458514522103. Epub 2014 Feb 3.</mixed-citation><mixed-citation xml:lang="en">Zhao S, Mutch K, Elsone L, et al. Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life. Mult Scler. 2014 Oct;20(12):1658-61. doi: 10.1177/1352458514522103. Epub 2014 Feb 3.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bradl M, Kanamori Y, Nakashima I, et al. Pain in neuromyelitis optica-prevalence, pathogenesis and therapy. Nat Rev Neurol. 2014 Sep;10(9):529-36. doi: 10.1038/nrneurol.2014.129. Epub 2014 Jul 29.</mixed-citation><mixed-citation xml:lang="en">Bradl M, Kanamori Y, Nakashima I, et al. Pain in neuromyelitis optica-prevalence, pathogenesis and therapy. Nat Rev Neurol. 2014 Sep;10(9):529-36. doi: 10.1038/nrneurol.2014.129. Epub 2014 Jul 29.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wingerchuk DM, Banwell B, Bennett JL, et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19.</mixed-citation><mixed-citation xml:lang="en">Wingerchuk DM, Banwell B, Bennett JL, et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. Epub 2015 Jun 19.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SM, Go MJ, Sung JJ, et al. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol. 2012 Aug;69(8):1026-31. doi: 10.1001/archneurol.2012.112</mixed-citation><mixed-citation xml:lang="en">Kim SM, Go MJ, Sung JJ, et al. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol. 2012 Aug;69(8):1026-31. doi: 10.1001/archneurol.2012.112</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Asseyer S, Cooper G, Paul F. Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. Front Neurol. 2020 Aug 21;11:778. doi: 10.3389/fneur.2020.00778</mixed-citation><mixed-citation xml:lang="en">Asseyer S, Cooper G, Paul F. Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. Front Neurol. 2020 Aug 21;11:778. doi: 10.3389/fneur.2020.00778</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci. 2006;29:507-38. doi: 10.1146/annurev.neuro.29.051605</mixed-citation><mixed-citation xml:lang="en">Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci. 2006;29:507-38. doi: 10.1146/annurev.neuro.29.051605</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lewin GR, Nykjaer A. Pro-neurotrophins, sortilin, and nociception. Eur J Neurosci. 2014 Feb;39(3):363-74. doi: 10.1111/ejn.12466</mixed-citation><mixed-citation xml:lang="en">Lewin GR, Nykjaer A. Pro-neurotrophins, sortilin, and nociception. Eur J Neurosci. 2014 Feb;39(3):363-74. doi: 10.1111/ejn.12466</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Шушарина НН, Патрушев МВ, Силина ЕВ и др. Экспрессия генов транспортеров нейромедиаторов в астроцитах разных отделов головного мозга в эксперименте. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;118(6):58-64. doi: 10.17116/jnevro20181186158</mixed-citation><mixed-citation xml:lang="en">Shusharina NN, Patrushev MV, Silina EV, et al. Expression of genes for neurotransmitter transporters in astrocytes in different brain regions in experiment. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6):58-64. doi: 10.17116/jnevro20181186158 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Зайцева ПА, Бойко АН. Заболевания спектра оптиконевромиелита: от патогенеза к таргетной терапии. Неврология, нейропсихиатрия, психосоматика. 2023;15(Прил. 1):49-57. doi: 10.14412/2074-2711-2023-1S-49-57</mixed-citation><mixed-citation xml:lang="en">Zaitseva PA, Boyko AN. Neuromyelitis optic spectrum disorders (NMOSD): from pathogenesis to targeted therapy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(Suppl. 1):49-57. doi: 10.14412/2074-2711-2023-1S-49-57 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Wang T, Lian Z, Wu X, et al. Subcortical structural abnormalities in female neuromyelitis optica patients with neuropathic pain. Mult Scler Relat Disord. 2020 Jan;37:101432. doi: 10.1016/j.msard.2019.101432. Epub 2019 Oct 5.</mixed-citation><mixed-citation xml:lang="en">Wang T, Lian Z, Wu X, et al. Subcortical structural abnormalities in female neuromyelitis optica patients with neuropathic pain. Mult Scler Relat Disord. 2020 Jan;37:101432. doi: 10.1016/j.msard.2019.101432. Epub 2019 Oct 5.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Pekcevik Y, Mitchell CH, Mealy MA, et al. Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. Mult Scler. 2016 Mar;22(3):302-11. doi: 10.1177/1352458515591069. Epub 2015 Jul 24.</mixed-citation><mixed-citation xml:lang="en">Pekcevik Y, Mitchell CH, Mealy MA, et al. Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. Mult Scler. 2016 Mar;22(3):302-11. doi: 10.1177/1352458515591069. Epub 2015 Jul 24.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hayashida S, Masaki K, Yonekawa T, et al. Early and extensive spinal white matter involvement in neuromyelitis optica. Brain Pathol. 2017 May;27(3):249-65. doi: 10.1111/bpa.12386. Epub 2016 Jun 29.</mixed-citation><mixed-citation xml:lang="en">Hayashida S, Masaki K, Yonekawa T, et al. Early and extensive spinal white matter involvement in neuromyelitis optica. Brain Pathol. 2017 May;27(3):249-65. doi: 10.1111/bpa.12386. Epub 2016 Jun 29.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Krampla W, Aboul-Enein F, Jecel J, et al. Spinal cord lesions in patients with neuromyelitis optica: a retrospective longterm MRI follow-up study. Eur Radiol. 2009 Oct;19(10):2535-43. doi: 10.1007/s00330-009-1425-3. Epub 2009 May 5.</mixed-citation><mixed-citation xml:lang="en">Krampla W, Aboul-Enein F, Jecel J, et al. Spinal cord lesions in patients with neuromyelitis optica: a retrospective longterm MRI follow-up study. Eur Radiol. 2009 Oct;19(10):2535-43. doi: 10.1007/s00330-009-1425-3. Epub 2009 May 5.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Masters-Israilov A, Robbins MS. Headache in Neuromyelitis Optica. Curr Pain Headache Rep. 2017 Apr;21(4):20. doi: 10.1007/s11916-017-0620-1</mixed-citation><mixed-citation xml:lang="en">Masters-Israilov A, Robbins MS. Headache in Neuromyelitis Optica. Curr Pain Headache Rep. 2017 Apr;21(4):20. doi: 10.1007/s11916-017-0620-1</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Asgari N, Skejoe HP, Lillevang ST, et al. Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study. BMC Neurol. 2013 Apr 8;13:33. doi: 10.1186/1471-2377-13-33</mixed-citation><mixed-citation xml:lang="en">Asgari N, Skejoe HP, Lillevang ST, et al. Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study. BMC Neurol. 2013 Apr 8;13:33. doi: 10.1186/1471-2377-13-33</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Messlinger K, Ebersberger A, Schaible HG. Release of immunoreactive substance P in the brain stem upon stimulation of the cranial dura mater with low pH – inhibition by the serotonin (5-HT1) receptor agonist CP 93,129. Br J Pharmacol. 1998 Dec;125(8):1726-32. doi: 10.1038/sj.bjp.0702247</mixed-citation><mixed-citation xml:lang="en">Messlinger K, Ebersberger A, Schaible HG. Release of immunoreactive substance P in the brain stem upon stimulation of the cranial dura mater with low pH – inhibition by the serotonin (5-HT1) receptor agonist CP 93,129. Br J Pharmacol. 1998 Dec;125(8):1726-32. doi: 10.1038/sj.bjp.0702247</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Asseyer S, Schmidt F, Chien C, et al. Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin. 2018 Aug 30;4(3):2055217318796684. doi: 10.1177/2055217318796684</mixed-citation><mixed-citation xml:lang="en">Asseyer S, Schmidt F, Chien C, et al. Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin. 2018 Aug 30;4(3):2055217318796684. doi: 10.1177/2055217318796684</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Mealy MA, Kozachik SL, Levy M. Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder. Pain Manag Nurs. 2019 Dec;20(6):580-91. doi: 10.1016/j.pmn.2019.03.003. Epub 2019 May 15.</mixed-citation><mixed-citation xml:lang="en">Mealy MA, Kozachik SL, Levy M. Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder. Pain Manag Nurs. 2019 Dec;20(6):580-91. doi: 10.1016/j.pmn.2019.03.003. Epub 2019 May 15.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Elsone L, Townsend T, Mutch K, et al. Neuropathic pruritus (itch) in neuromyelitis optica. Mult Scler. 2013 Apr;19(4):475-9. doi: 10.1177/1352458512457720. Epub 2012 Aug 30.</mixed-citation><mixed-citation xml:lang="en">Elsone L, Townsend T, Mutch K, et al. Neuropathic pruritus (itch) in neuromyelitis optica. Mult Scler. 2013 Apr;19(4):475-9. doi: 10.1177/1352458512457720. Epub 2012 Aug 30.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Eaneff S, Wang V, Hanger M, et al. Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community. Mult Scler Relat Disord. 2017 Oct;17:116-22. doi: 10.1016/j.msard.2017.07.014. Epub 2017 Jul 11.</mixed-citation><mixed-citation xml:lang="en">Eaneff S, Wang V, Hanger M, et al. Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community. Mult Scler Relat Disord. 2017 Oct;17:116-22. doi: 10.1016/j.msard.2017.07.014. Epub 2017 Jul 11.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Rodriguez-Quiroga SA, Abaroa L, Arakaki T, et al. Commentary on neuromyelitis optica associated with painful paroxysmal dystonia: case report and literature review. Acta Neurol Belg. 2015 Sep;115(3):523-4. doi: 10.1007/s13760-014-0389-5. Epub 2014 Nov 9.</mixed-citation><mixed-citation xml:lang="en">Rodriguez-Quiroga SA, Abaroa L, Arakaki T, et al. Commentary on neuromyelitis optica associated with painful paroxysmal dystonia: case report and literature review. Acta Neurol Belg. 2015 Sep;115(3):523-4. doi: 10.1007/s13760-014-0389-5. Epub 2014 Nov 9.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Carnero Contentti E, Leguizamon F, Hryb JP, et al. Neuromyelitis optica: association with paroxysmal painful tonic spasms. Neurologia. 2016 Oct;31(8):511-5. doi: 10.1016/j.nrl.2014.12.001. Epub 2015 Feb 3.</mixed-citation><mixed-citation xml:lang="en">Carnero Contentti E, Leguizamon F, Hryb JP, et al. Neuromyelitis optica: association with paroxysmal painful tonic spasms. Neurologia. 2016 Oct;31(8):511-5. doi: 10.1016/j.nrl.2014.12.001. Epub 2015 Feb 3.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Tüzün E, Akman-Demir G, Eraksoy M. Paroxysmal attacks in multiple sclerosis. Mult Scler. 2001 Dec;7(6):402-4. doi: 10.1177/135245850100700609</mixed-citation><mixed-citation xml:lang="en">Tüzün E, Akman-Demir G, Eraksoy M. Paroxysmal attacks in multiple sclerosis. Mult Scler. 2001 Dec;7(6):402-4. doi: 10.1177/135245850100700609</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
